Skip to main content

Advertisement

SpringerLink
Log in

Worldwide Impact of the Human Papillomavirus Vaccine

  • Gynecologic Tumors
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Nearly 500,000 new cases of cervical cancer and 274,000 cervical cancer deaths are occurring worldwide each year. Approximately 80% of the 500,000 new cases occur in developing countries and this percentage is expected to increase to 90% by 2020. In developing countries, cervical cancer tends to affect relatively young poor women and is the single largest cause of years of life lost to cancer, since screening and treatment programs, and health care, in general, are relatively inaccessible to these women. Each 5-year delay in vaccinating women against HPV may lead to the deaths of 1.5 to 2 million women from cervical cancer in developing countries. The high efficacy of the two available cervical cancer vaccines and their proven ability to reduce the incidence of cervical cancer precursor lesions offer hope that the vaccine will have enormous worldwide impact and may dramatically reduce the cervical cancer burden. The current vaccines protecting against HPV-16 and HPV-18 may prevent up to 70% of new cervical cancers. Vaccine cross-reactivity for HPV-31, -33, -45, and -52 suggest that an even higher percentage of cervical cancers might be prevented with its use. Currently, the prohibitive cost of the vaccine precludes its widespread implementation. Cooperation between governments, international health organizations, and the vaccine industry is needed to overcome this significant barrier so that women are no longer denied a potentially life-saving advance. Worldwide HPV vaccination and cervical cancer screening should be made an international priority.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Centers for Disease Control and Prevention: Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007, 56(Early Release): 1–24.

    Google Scholar 

  2. ACOG Practice Bulletin: Practice Bulletin: Clinical management guidelines for obstetricians-gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005, 105:905–918.

    Google Scholar 

  3. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55, 74–108 (2005). doi:10.3322/canjclin.55.2.74

    Article  PubMed  Google Scholar 

  4. Pagliusi SR, Teresa Aguado M: Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23, 569–578 (2004). doi:10.1016/j.vaccine.2004.07.046

    Article  PubMed  Google Scholar 

  5. Agosti JM, Goldie SJ: Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med 356(19), 1908–1910 (2007)

    Article  PubMed  CAS  Google Scholar 

This is a thought-provoking companion article to the FUTURE I and FUTURE II NEJM studies discussing the key challenges to introducing the HPV vaccine in developing countries.

  1. Bosch FX, Lorncz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papilloma virus in cervical cancer. J Clin Pathol 55, 244–265 (2002)

    PubMed  CAS  Google Scholar 

  2. Koutsky LA, Ault KA, Wheeler CM et al.: A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 347, 1645–1651 (2002)

    Article  PubMed  CAS  Google Scholar 

  3. Bayas J-M, Costas L, Munoz A: Cervical cancer indications, efficacy, and side effects. Gynecol Oncol 110, S11–S14 (2008)

    Article  PubMed  CAS  Google Scholar 

  4. De Sanjose S, Diaz M, Catellsague X et al.: Worldwide prevalence and genotype distribution of cervical human papilloma virus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7), 453–459 (2007)

    Article  PubMed  Google Scholar 

  5. Jemal A, Tiwari RC, Murray T et al.: Cancer statistics, 2004. CA Cancer J Clin 54, 8–29 (2004)

    Article  PubMed  Google Scholar 

  6. Clavel C, Masure M, Bory JP et al.: Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84, 48–55 (2001)

    Article  Google Scholar 

  7. Hutchison ML, Zahniser DJ, Sherman ME et al.: Utility of liquid-based cytology for cervical cancer screening: results of a populations-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 87, 48–55 (1999)

    Article  Google Scholar 

  8. Harper DM: Impact with Cervarix on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of age. Gynecol Oncol 110, S11–S17 (2008)

    Article  PubMed  CAS  Google Scholar 

  9. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367, 1247–1255 (2006)

    Article  PubMed  CAS  Google Scholar 

  10. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356, 1928–1943 (2007)

    Article  PubMed  CAS  Google Scholar 

  11. Future II Study Group.: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915–1927.

    Article  Google Scholar 

  12. Paavanen J, Jenkins D, Bosch FX et al.: Efficacy of a prophylactic adjuvant bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase II double-blind, randomized controlled trial. Lancet 369, 2161–2170 (2007)

    Article  Google Scholar 

  13. Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BM: Initial lessons learned in HPV vaccination. Gynecol Oncol 109, S4–S11 (2008)

    Article  PubMed  Google Scholar 

This is an excellent article examining patients’ and parents’ awareness and attitudes of HPV vaccination in the United States and describing misperceptions and barriers such as costs related to the worldwide introduction of the HPV vaccine.

  1. Jenkins D: A review of cross-protections against oncogenic HPV by an HPV-16/18 ASO4-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 110, S18–S25 (2008)

    Article  PubMed  CAS  Google Scholar 

  2. Castellsague X, Mendez C, Loscertales MP et al.: Human papillomavirus genotypes in rural Mozambique. Lancet 358, 1429–1430 (2001)

    Article  PubMed  CAS  Google Scholar 

  3. Naucler P, Mabotada Costa F, Ljungberg O, Bugalho A, Dillner J: Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 85, 2189–2190 (2004)

    Article  PubMed  CAS  Google Scholar 

  4. Diaz M, Kim JJ, Albero G, Clifford G, Bosch FX, Goldie SJ: Health and economic impact of HPV-16 and-18 vaccination and cervical cancer screening in India. Br J Cancer 99, 230–238 (2008)

    Article  PubMed  CAS  Google Scholar 

  5. Sankaranarayanan R, Bhatla N, Gravitt PE et al.: Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka, and Nepal. Vaccine 26S, M43–M52 (2008)

    Article  Google Scholar 

  6. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality, and prevalence worldwide. IARC Cancer Base No 5 Version 2.0. Lyon: IARC Press; 2004.

  7. Franceschi S, Rajkumar R, Snijders PJ et al.: Papillomavirus infection in rural women in southern India. Br J Cancer 92, 601–606 (2005)

    Article  PubMed  CAS  Google Scholar 

  8. Clifford GM, Galluss S, Herrero R et al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991–998 (2005)

    Article  PubMed  CAS  Google Scholar 

  9. Sankaranarayanan R, Nene BM, Dinshaw KA et al.: A cluster randomized control trial of visual, cytology, and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116, 617–623 (2005)

    Article  PubMed  CAS  Google Scholar 

  10. Sankaranarayanan R, Chatterji R, Shastri SS et al.: Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer 112, 341–347 (2004)

    Article  PubMed  CAS  Google Scholar 

  11. Sowjanya AP, Jain M, Poli UR et al.: Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 5, 116 (2005)

    Article  PubMed  Google Scholar 

  12. Laikangbam P, Sengupta S, Bhattacharya P et al.: A comparative profile of the prevalence and age distribution of human papilloma virus type 16/18 infections among three states of India with focus on northeast India. Int J Gynecol Cancer 17(1), 107–117 (2007)

    Article  PubMed  CAS  Google Scholar 

  13. De Silva R, Karunaratne K, Mendis LN, Ramesh R, Chow VT: PCR detection and typing of human papilloma virus DNA in squamous carcinoma of the cervix in a cohort of Sri Lankan women. Ceylon Med J 51, 114–117 (2006)

    PubMed  Google Scholar 

  14. Munoz N, Franco EL, Herrero R et al.: Recommendations for Cervical cancer prevention in Latin America and the Caribbean. Vaccine 26S, L96–L107 (2008)

    Article  Google Scholar 

  15. Smith JS, Lindsay L, Hoots B et al.: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3), 621–632 (2007)

    Article  PubMed  CAS  Google Scholar 

  16. Goldie SJ, Diaz M, Kim S-Y, Levin CE, Van Minh H, Kim JJ: Mathematical models of cervical cancer prevention in the Asia Pacific Region. Vaccine 26S, M17–M29 (2008)

    Article  Google Scholar 

  17. Pham Th, Nguyen TH, Herrero R et al.: Human Papilloma Virus infection among women in South and North Vietnam. Int J Cancer 104(2), 213–220 (2003)

    Article  PubMed  Google Scholar 

  18. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papilloma virus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1), 63–73 (2003)

    Article  PubMed  CAS  Google Scholar 

  19. Grce M, Davies P, Anttila A et al.: Report on the 2007 International workshop on Human papillomaviruses and consensus recommendations for cervical cancer prevention. Cent Eur J Pub Health 16(1), 38–40 (2008)

    Google Scholar 

  20. Arbyn M, Primix-Zakelj M, Raifu AO et al.: The burden of cervical cancer in South-East Europe at the beginning of the 21st century. Coll Antropol 31(Suppl 2), 7–10 (2007)

    PubMed  Google Scholar 

  21. Znaor A, Strnad M: Cervical cancer in Croatia; state of the art and possibilities for prevention. Coll Antropol 31(Suppl 2), 37–40 (2007)

    PubMed  Google Scholar 

  22. Croatian National Institute of Public Health Zagreb. 1983–2006; No. 1–29.

  23. Milutin-Gasperov N, Sabol I, Halec G, Matovina M, Grce M: Retrospective study of the prevalence of high-risk human papilloma viruses among Croatian women. Coll Antropol 31(suppl 2), 89–96 (2007)

    PubMed  Google Scholar 

  24. Munoz N, Bosch FX, Castellsague X et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111, 278–285 (2004)

    Article  PubMed  CAS  Google Scholar 

  25. Batson A, Meheus F, Brooke S: Chapter 26: innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 24(S3), 219–225 (2006)

    Article  Google Scholar 

This is a comprehensive article on the ways that vaccines are financed in countries worldwide and specifically on how the HPV vaccine could be financed in developing countries.

  1. Garnett GP, Kim JJ, French K, Goldie SJ: Chapter 21: modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24(Suppl 3), S178–S186 (2006)

    Article  Google Scholar 

  2. World Bank Development Data. http://devedata.worldbank.org/hnpstats/query/default.html.

  3. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 359(8), 821–832 (2008)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Methodist Hospital, Houston, TX, USA

    Amy A. Hakim MD, MS & Tri A. Dinh MD

Authors
  1. Amy A. Hakim MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tri A. Dinh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tri A. Dinh MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hakim, A.A., Dinh, T.A. Worldwide Impact of the Human Papillomavirus Vaccine. Curr. Treat. Options in Oncol. 10, 44–53 (2009). https://doi.org/10.1007/s11864-009-0094-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0094-4

Keywords

Search

Navigation